Aaron Weitzman

The company operates under a shared revenue model with its health care provider customers.

The company collected first-round bids this week.

It's the highest quarterly investment in the space since the second quarter of 2022.

The company says it is on track to become cash-flow positive by the first half of 2026.

This week we brought you

Food-as-medicine is at a crossroads between likely federal funding cuts and increased focus on healthy lifestyle changes on the other

This week we delivered

Pharma's need for efficient clinical trials has never been more stark amid FDA upheaval.

The growing fertility space is attracting substantial investments from both venture capital and private equity. Go deeper (1 min. read)

Hims & Hers plans to expand